Kornimate/medical-research-clean huggingface dataset:
effectiveness of soft tissue mobilization

Conditions: Tension-Type Headache

Summary: the aim of this study was to determine the effects of soft tissue mobilization and trigger point release verses stretching in tension-type headache among university students. two randomized groups of participants with tension type headache will be treated with combination therapy of soft tissue mobilization and trigger point release therapy after the application of hot-pack in experimental group while control group received stretching of cervical muscles after hot-pack application .both, male and female patients meeting the inclusion criteria will be included. patients having malignancy and cervical tumor will be excluded.

it was a randomized control trial study. study setting was bashir institute of health sciences. inclusion criteria was age 18 to 25 year's students, with tension type headache and trigger point in neck muscles. 30 subjects were randomly and equally allocated to experimental group (n=15) and control group (n=15) through toss and coin method. outcomes include cervical range of motions were measured by goniometer and vas for paini.e., used at baseline and at the final session for duration of 3 weeks.

Eligibility criteria:
inclusion criteria: * age between 18-25 years. * both male and female gender * trigger points in neck muscles exclusion criteria: * patients taking pharmacologicaldrugs. * presence of co morbidities. * malignancy/ trauma in cervical region * skin infections or open wound in cervical region
preventing acquired resistance: strengthen tb treatment by adding amikacin in the first treatment week of multidrug-resistant tuberculosis

Conditions: Tuberculosis, Multidrug-Resistant

Summary: acquired drug-resistance is a major challenge for tuberculosis (tb) care programs. the 2020 who guidelines recommends replacing second-line injectables by bedaquiline in rifampicin-resistant tb (rr-tb) treatment regimens. however, recent reports show too high rates of acquired bedaquiline resistance. this may be explained by the delayed onset of action of bedaquiline. the investigators will study whether high-dose amikacin (a second-line injectable), administered during the first week of rr-tb treatment, is safe in 20 patients treated for rr-tb in rwanda. if safe, further studies will assess whether adding amikacin in the first treatment week protect against acquired bedaquiline resistance. this study is embedded in an ongoing "master study" of the shorrt (short oral rr-tb) treatment regimen in rwanda, a before/after study, with a retrospective cohort (before; the previously recommended second-line injectable-containing rr-tb regimen) and a prospective cohort (after: the newly recommended shorrt regimen).


Eligibility criteria:
inclusion criteria: * enrolled in the master shorrt study * able and willing to provide written informed consent for the present substudy "stake" exclusion criteria: * any audiometry abnormality (grade 1 or higher) on baseline audiometry * history of kidney disease or baseline creatinine clearance below or equal to 60ml/min * pregnant or breastfeeding women * history of previous injectable based tuberculosis treatment (including with streptomycin) * \ 65 years old * patient on nsaid or on diuretics master shorrt study inclusion criteria: * is willing and able to give informed consent to be enrolled in the research project and for follow-up * has bacteriologically or molecularly confirmed tb with evidence of resistance to at least rifampicin exclusion criteria: * is unable to take oral medication; * must take any medications contraindicated with the medicines in the mdr/rr-tb regimen; * has a known allergy to any of the drugs in the mdr/rr-tb regimen; * has a qtcf interval of ≥ 500 msec; at baseline that does not correct with medical management.

Keywords: multidrug- and rifampicin-resistant tuberculosis
the predictive value of the sperm chromatin dispersion test, halosperm®, before and after sperm preparation for clinical pregnancy in cases of unexplained infertility treated with intra-uterine insemination (first cycle) and ovulation induction with clomiphene citrate.

Conditions: Unexplained Infertility

Summary: recent research has revealed that subtle abnormalities can be found in sperm samples that seem to be normal with conventional analysis techniques. the dna in the sperm heads is sometimes fragmented and this may be the reason why couples with a diagnosis of unexplained infertility do not achieve pregnancy. we are planning a study to examine the incidence of dna fragmentation in the sperm of couples with previously unexplained infertility. in a first treatment cycle with intra-uterine insemination the percentage of dna fragmentation in sperm will be measured. afterwards the results of the patients who are pregnant will be compared with those of the not pregnant ones. we expect to find differences between both groups. 100 patients will be included in the study.


Eligibility criteria:
inclusion criteria: * unexplained infertility, i.e. female patients with ovulatory cycles and patent tubes; normal sperm analysis (who criteria). * patient agrees to have a first treatment cycle with intra-uterine insemination and ovulation-induction with clomiphene citrate.
bilicam clinical validation study

Conditions: Newborn Jaundice

Summary: the goal of this study is to assess the accuracy of bilicam, a non-invasive technology based on analysis of digital images obtained with an app installed on a commercial smartphone, in estimating total serum bilirubin levels in newborns. bilicam estimated bilirubin levels will be compared to total serum bilirubin levels in up to 225 newborns.

jaundice, a yellowing of the skin and eyes caused by a build up of bilirubin in the blood, is a common problem in newborn infants. measurement of total serum bilirubin (tsb) levels is used for clinical decision making. bilicam is a non-invasive technology used to estimate tsb levels in newborns. with bilicam, the user obtains digital images of a small portion of a newborn's skin using the bilicam app installed on a commercial smartphone in a standardized manner. a color calibration card is placed on the baby's sternum to account for varying light conditions. data on color levels in the photos are used to estimate a bilirubin level. for the study, paired bilicam estimated bilirubin (bcb) and tsb levels will be compared on a racially and ethnically diverse sample of newborns. recruitment will continue until 225 newborns have completed the study.

Eligibility criteria:
inclusion criteria: * newborn born at ≥ 35 weeks gestation * parent speaks and reads english * parent provides written informed consent exclusion criteria: * previous or ongoing treatment with phototherapy for hyperbilirubinemia * medical or other complications that preclude completion of the study
decision aids for tamoxifen treatment in breast cancer patients

Conditions: Breast Cancer

Summary: this is an educational intervention study for breast cancer patients who undergo tamoxifen treatment. the purpose of the study is to assess the impact of decision aids (da) on the patients' decision-making process, compliance on drug, and knowledge regarding tamoxifen treatment. patients will randomly assign to da group or conventional group. both groups will have baseline questionnaire surveys before starting tamoxifen treatment, and 4 weeks later follow-up questionnaire surveys.


Eligibility criteria:
inclusion criteria: * breast cancer patients who are recommended to undergo tamoxifen treatment in national cancer center, korea * - age at least 18 years and more exclusion criteria: * age under 18 years * inability to read or speak korean * disagree to provide a written informed consent

Keywords: breast neoplasms tamoxifen decision aids
the impact of rehabilitation on quality of life in visually impaired

Conditions: Blindness

Summary: the project has four primary objectives: 1) determine if blind rehabilitation improves the quality of life of legally blind veterans; 2) determine the relationship between quality of life and visual function; 3) determine if factors, such as cognitive status, level of depression, age and the presence of additional medical conditions besides vision loss, intervention of blind rehabilitation extends beyond the visually impaired individual and improve the quality of life of their primary caregiver (e.g. spouse, partner, family member or friend.)


Eligibility criteria:
visually impaired

Keywords: vision, quality of life
direct comparison of 2d cardiac pet with 3d cardiac pet

Conditions: Coronary Artery Disease

Summary: lowering the per-infusion dose of rb-82 offers advantages of lessening radiation exposure and extending useable generator life. prior studies have not shown equivalence of 3d vs 2d rb-82 pet. the investigators therefore compare 3d pet after a lower rb-82 dose (\~20 mci) processed using a monte-carlo driven scatter correction algorithm against conventional higher dosage (\~50 mci) 2d rb-82 pet mpi.

this study re-examines 2d an 3d myocardial perfusion pet data from 19 subjects, mean age 65 years, mean bmi 30 kg/m2, 79% male. rest and stress scans were acquired on a siemens accel™ pet scanner in 2d (septa extended) and 3d (septa retracted) modes. rb-82 doses were rest 53+/-5 mci and stress 53+/-6 mci. imaging times were 2d emission scan for 3 mins (90 sec delay post rb-82 infusion), followed by a 3 minute, 3d gated emission scan (180 sec delay). decay and shorter acquisition times led to a 62% reduction in the effective dosage 2d vs 3d datasets. 3d images were first pre-processed using a monte-carlo scatter and prompt gamma correction algorithm (imagen3d™) then reconstructed using imagenprotm (cvit, kansas city, mo). reconstructed images were evaluated using relative, 17 segment raw scores (cedars qpet). studies were read by consensus of 2-blinded readers for: image quality (1-4, poor-excellent), interpretive certainty (1-3, low-high) and rest perfusion using a 17 segment model (0=normal; 1-3 = mild, moderate, or severe perfusion defects). stress segmental scores were not evaluated due to differences in imaging start time post dipyridamole infusion.

Eligibility criteria:
inclusion criteria: * \>18 years of age * have ability to provide informed consent * have a technically adequate rest/stress rb-82 perfsion pet study within the past 60 days exclusion criteria: * pregnant or nursing feamle * weight \> 275 lbs * have contraindications to adenosine stress testing * unstable cardiac rhythm (atrial fibrillation, frequent pvcs * ptca or cabg within the last 60 days

Keywords: myocardial perfusion imaging pet rb-82
absorption and systematic pharmacokinetics of topically applied idp-120 gel

Conditions: Acne

Summary: study designed to assess the safety and plasma pk of tretinoin and its metabolites from topically applied idp-120 gel.

an open-label study designed to assess the safety and plasma pk of tretinoin and its metabolites from topically applied idp-120 gel.

Eligibility criteria:
key inclusion criteria: * male or female between the ages of 9 and \<17 (16 years 11 months) * written and verbal informed consent must be obtained. subjects less than age of consent must sign an assent for the study and a parent or legal guardian must sign the informed consent. * subject must have a score of 3 (moderate) or 4 (severe) on the evaluator's global severity assessment. * subject with facial acne inflammatory lesion count no less than 20 but no more than 40. * subject with facial acne non-inflammatory lesion count no less than 20 but no more than 100. key exclusion criteria: * use of an investigational drug or device within 30 days of enrollment, previous participation in a research study with idp-120 gel, or participation in a research study concurrent with this study. * any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobate, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis. * any underlying disease or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion counts inconclusive. * subjects with a facial beard or mustache that could interfere with the study assessments * subjects with more than 2 facial nodules.
better effectiveness after transition - heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to compare the effect of implementing wireless remote monitoring combined with structured telephone monitoring, versus current care, on variation in rehospitalization among older patients hospitalized with heart failure at six medical centers.


Eligibility criteria:
inclusion criteria: * patients hospitalized at any of the six medical centers who are being actively treated for heart failure. exclusion criteria: * patients who have previously received a transplant, are being evaluated for a transplant, or who are on the wait list for a transplant, * patients who are enrolled or enrolling in hospice, or are expected to expire shortly after discharge, * patients with dementia, * patients who are admitted from a skilled nursing facility (snf), or who we anticipate will be discharged to a long term stay in a snf, * patients who do not have a working land line phone or reliable cell service, * patients on chronic dialysis, * patients who cannot identify a usual source of care (free clinic is acceptable) and who will not be assigned a provider upon discharge, * patients with the following cardiovascular conditions: patients with valvular disorders requiring surgical intervention (except for those with incidental valvular disease, who will be included), acute myocardial infarction (except for those with demand ischemia, who will be included), percutaneous coronary intervention * patients expected to enroll in hospice or expire after discharge, * patients who are unable to use the intervention equipment (e.g., unable to stand on the weight scale), or who are otherwise unable to comply with the intervention
high dose chemotherapy and autologous transplant for neuroblastoma

Conditions: Neuroblastoma

Summary: this is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for children's oncology group (cog) studies.

this therapy involves the use of melphalan, etoposide, and carboplatin (consolidation chemotherapy); autologous stem cell rescue, post-transplant radiation therapy and a maintenance phase with isotretinoin (accutane, 13-cis-retinoic acid) therapy. if available, patients should also consider post-transplant therapy with cytokines and monoclonal antibody (ch14.18) on a cog or new approaches to neuroblastoma therapy (nant) trial.

Eligibility criteria:
inclusion criteria: * less than 30 years of age at diagnosis of neuroblastoma * no evidence of disease progression: defined as increase in tumor size of \>25% or new lesions * recovery from last induction course of chemotherapy (absolute neutrophil count \> 500 and platelet \> 20,000) * no uncontrolled infection * minimum frozen peripheral blood stem cells (pbscs) of 2 x 10\^6 cd34 cells/kg for transplant are mandatory and 2 x 10\^6 cd34 cells/kg for back-up are strongly recommended (thus, pbsc of 4 x 106 cd34 cells/kg is encouraged) * adequate organ function defined as: * hepatic: aspartate aminotransferase (ast) \ 60 ml/min/1.73m\^2 if a creatinine clearance is performed at end induction and the result is \< 100 ml/min/1.73m\^2, a gfr must then be performed using a nuclear blood sampling method or iothalamate clearance method. camera method is not allowed as measure of gfr prior to or during consolidation therapy for patients with gfr or creatinine clearance of \< 100 ml/min/1.73m\^2 exclusion criteria * patients with progressive disease should consider participating in phase i studies since consolidation therapy using the regimen outlined in this document have not been determined to be useful. * patients who are delayed in consolidation chemotherapy beyond 8 weeks, and don't meet organ function criteria.

Keywords: peripheral blood stem cell transplantation autologous stem cell transplant
bacteriuria and indwelling urinary catheter.

Conditions: Bacteriuria Asymptomatic; Urinary Tract Infections

Summary: investigation of 1. the incidence of symptomatic bacteriuria during four weeks after removal of an iuc in inpatients at a rehabilitation clinic for patients ≥ 65 years compared with the incidence of symptomatic bacteriuria among inpatients not treated with an iuc and 2. for how long does abu persist in inpatients at a rehabilitation clinic for patients ≥ 65 years during a follow-up time of four weeks after iuc-removal?


Eligibility criteria:
inclusion criteria: * admission to a rehabilitation clinic for patients ≥ 65 years in stockholm county, sweden * ability to understand oral and written instructions in swedish * ability to produce a voided urine-sample exclusion criteria: * severe cognitive failure and/or disability to understand oral and written instructions in swedish according to the healthcare-personnel's judgment at the ward * end-of-life care * physical disability to produce voided urine-samples * ongoing antimicrobial treatment for symptomatic bacteriuria

Keywords: urinary catheter
clinical trial to determine the bioavailability of three different zinc preparations

Conditions: Zinc Deficiency

Summary: the main objective of this clinical is to get information on pharmacokinetics of zinc-enriched yeast.the bioavailability of the yeast enriched with zinc will be compared to two selected zinc salts used in food supplements that are zinc oxide and zinc gluconate.


Eligibility criteria:
inclusion criteria: * subject is able and willing to sign the informed consent form prior to screening evaluations * sex: female (premenopausal), male * age: 20 - 50 years * bmi ≥19 or ≤30 kg/m² * non-smoker * subject is in good physical and mental health as established by medical history, physical examination, electrocardiogram, vital signs, results of biochemistry, hematology exclusion criteria: * relevant history or presence of any medical disorder, potentially interfering with this trial * for this trial clinically relevant abnormal laboratory, ecg, vital signs or physical findings at screening * migraine or regular headache, intense premenstrual symptoms * coffee consumption \>3 cups / day * blood donation within 2 months prior to trial start or during trial * regular intake of mineral supplements within 4 weeks prior to trial start or during trial * chronic intake of substances affecting the intestinal absorption of zinc * vegetarians / vegans * drug-, alcohol- and medication abuses * known hiv-infection * known acute or chronic hepatitis b and c infection * relevant allergy or known hypersensitivity against compounds of the study preparations, for example lactose intolerance * known pregnancy, breast feeding or intention to become pregnant during the study * participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial * not anticipating any planned changes in lifestyle for the duration of the study

Keywords: zinc/pharmacokinetics
improved post-transplant cyclophosphamide regimens for pediatric patients with refractory aml

Conditions: Hematopoietic System--Cancer

Summary: no more datas about post-transplant cyclophosphamide (pt/cy) used in pediatric refractory acute myeloid leukemia (r-aml）patients. investigators reasoned that this group of patients if they have been treated with ablative conditioning regimens for hsct combined with pt/cy, under the rapid of immune reconstitution will have better outcomes.

haploidentical stem cell transplantation (hsct) is a potentially curative therapy for patients with high risk or refractory acute myeloid leukemia (r-aml). graft-versus-host disease （gvhd）is a major barrier to achieve success for patients with hsct. high dose cyclophosphamide given after hla-matched related and unrelated allogeneic stem cell transplantation for patients with hematologic malignancies is effective single agent (gvhd) prophylaxis in adults and in pediatric benign patients. data describing outcomes for pediatric maligant patients has not been reported. investigators have recruited 26 pediatric patients (3 years \< age \<18 years) between march 2015 to july 2018 with primary induction r-aml treated in investigators' institution for r-aml with modified myeloablative regimen, post-transplant cyclophosphamide (ptcy) has been used as gvhd prophylaxis. conditioning regimen of the group of patient consisted idrabine(ida,10mg/m2/day) which was administered intravenously for 2 days, from days -14 to -13, total body irritation (tbi, 9 gy) which was divided into 3 fractions and 3 days from -12 to -10, thymoglobulin (2.5mg/kg/day) was administered for 3 days, from -9 to -7, etoposide (vp-16, 300mg/m2) which was infused intravenously on day -6, cladribine (10mg/m2/day) which was administered for 3 days from -5 to -2 .

Eligibility criteria:
inclusion criteria: -refractory aml exclusion criteria: - complete remission aml

Keywords: hsct, aml， r-aml
the novel immunomodulatory and anticoagulant therapies for recurrent pregnancy loss

Conditions: Recurrent Pregnancy Loss

Summary: in this clinical cohort study, the investigators are going to observe the efficacy of anti-coagulation and immune therapy in the treatment of recurrent pregnancy loss with a prospective randomized controlled trial.


Eligibility criteria:
inclusion criteria: - woman who had 2 miscarriage before 12(th) week of gestation.the patient who is diagnosed as thrombophilia with recurrent pregnancy loss. signed consent form. exclusion criteria: 1. having experienced severe allergies, trauma history and/or operation history within 3 months. 2. with a history of mental illness and/or family history of mental illness limb disabled. 3. taking medicine within one month. 4. suffering major events or having mood swings. 5. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine) 6. chromosome aberrations in anyone of the couple. 7. patients who have drugs contraindications
tirofiban in stenting for long coronary lesion

Conditions: Coronary Artery Disease

Summary: periprocedural myonecrosis or infarction are associated with short, intermediate, and long term adverse outcomes. previous study indicated 12.6% of patients suffered a peri-procedural ck-mb rise by overlapping use of drug-eluting stents for long coronary lesions. here the investigators hypothesize that peri-procedural use of tirofiban could reduce the occurrence of periprocedural infarciton in elective patients with long coronary lesions treated by overlapping use of drug-eluting stents.

according to the results of 12.6% occurrence of peri-procedural myocardial infarction after long stent implantation by previous report\[international journal of cardiology 2009;134: 231-237\], the investigator hypothesize the 50% reduction of peri-procedural mi by using tirofiban. three hundred and sixty-nine patients in each group are needed to reach 80% of power with α 0.05.

Eligibility criteria:
inclusion criteria: * age between 18y\~80y, with symptomatic coronary disease * at least one lesion length more than 40mm to be treated by overlapping drug-eluting stents in major epicardial coronary vessel exclusion criteria: * aspirin or clopidogrel intolerance * lesions length less than 40mm, or overlapping stent length less than 40mm * bifurcation lesions need to be treated by two stents * patients with acute coronary syndrome and elevated baseline cardiac enzyme (ck-mb) * left ventricular ejection fraction less than 0.35 * baseline estimated gfr less than 30 * estimated life time less than one year * refuse to sign the informed consent

Keywords: coronary disease stents thrombosis myocardial infarction prognosis